Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
Anna Maria Fink1, Jasmin Bahlo1, Sandra Robrecht1, Othman Al-Sawaf1, Ali Aldaoud2, Holger Hebart3, Kathleen Jentsch-Ullrich4, Steffen Dörfel5, Kirsten Fischer1, Clemens-Martin Wendtner1,6, Thomas Nösslinger7, Paolo Ghia8, Francesc Bosch9,10, Arnon P Kater11,12, Hartmut Döhner13, Michael Kneba14, Karl-Anton Kreuzer1, Eugen Tausch13, Stephan Stilgenbauer13, Matthias Ritgen14
1Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital of Cologne, Cologne, Germany
2Gemeinschaftspraxis für Hämatologie und Onkologie, Leipzig, Germany
3Zentrum für Innere Medizin, Hämatologie/Onkologie, Stauferklinikum Schwäbisch-Gmünd, Germany
4Internistische Gemeinschaftspraxis, Magdeburg, Germany
5Onkologische Gemeinschaftspraxis, Dresden, Germany
6Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany
73rd Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
8Strategic Research Program on CLL, Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy
9Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
10on behalf of the Spanish Group of CLL (GELLC)
11Department of Hematology, Academic Medical Center Amsterdam, University of Amsterdam, Netherlands
12on behalf of the Dutch–Belgium HOVON CLL study group
13Department of Internal Medicine III, University of Ulm, Ulm, Germany
14Campus Kiel, 2nd Deptartment of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Haematology
Tập 4
e475-e486
Thông tin tác giả